Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR)

MLA

Paul Clement, et al. “Hypogonadism in Male Cancer Patients Treated with the Tyrosine Kinase Inhibitors Sunitinib (SUN) or Sorafenib (SOR).” Journal of Clinical Oncology, vol. 27, May 2009, p. 3565. EBSCOhost, https://doi.org/10.1200/jco.2009.27.15_suppl.3565.

APA

Paul Clement, Patrick Schöffski, Pascal Wolter, Herlinde Dumez, Dirk Vanderschueren, & Hans Wildiers. (2009). Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR). Journal of Clinical Oncology, 27, 3565. https://doi.org/10.1200/jco.2009.27.15_suppl.3565

Chicago

Paul Clement, Patrick Schöffski, Pascal Wolter, Herlinde Dumez, Dirk Vanderschueren, and Hans Wildiers. 2009. “Hypogonadism in Male Cancer Patients Treated with the Tyrosine Kinase Inhibitors Sunitinib (SUN) or Sorafenib (SOR).” Journal of Clinical Oncology 27 (May): 3565. doi:10.1200/jco.2009.27.15_suppl.3565.